Mantis Biotech is making ‘digital twins’ of humans to help solve medicine’s dataavailability problem

Mantis Biotech is developing 'digital twins' of humans using diverse data sources to address the scarcity of reliable medical data, particularly in rare diseases. Their platform creates predictive models that inform clinical decision-making, enhance sports performance insights, and aid drug discovery. Recently funded with $7.4 million, Mantis aims to expand its technology for broader biomedical applications.

Key Points

• Mantis Biotech's platform integrates various data sources to create digital twins of humans.
• The platform can assist in studying medical procedures, training surgical robots, and simulating medical scenarios.
• Large language models (LLMs) help synthesize data, improving research and diagnostics.
• Challenges remain with data availability, especially for rare diseases due to regulatory and ethical constraints.
• Mantis has found initial success in professional sports, particularly with an NBA team in performance analysis.
• The startup raised $7.4 million to fund tech development and market expansion.

Relevance

• Advancements in AI and LLMs as of 2025 are critical to improving healthcare data analytics and precision medicine.
• The increasing emphasis on digital health solutions reflects the ongoing trend towards integrating technology in patient care.
• Mantis' focus on synthetic data aligns with emerging strategies to address data scarcity in genomics and rare disease research.

Mantis Biotech is poised to transform biomedical research and sports analytics with its innovative approach to building digital twins, addressing significant data gaps while paving the way for enhanced predictive healthcare solutions.